ReviewInternational journal of rheumatic diseases2018
Adjunctive therapies in Kawasaki disease.
Review in International journal of rheumatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children.Frontiers in immunology · 2021Pooled it
- Learning-Based Models for Predicting IVIG Resistance and Coronary Artery Lesions in Kawasaki Disease: A Review of Technical Aspects and Study Features.Paediatric drugs · 2025Review
- Pharmacoeconomic Analysis and Considerations for the Management of Kawasaki Disease in the Arab Countries-A Multinational, Multi-Institutional Project of the Kawasaki Disease Arab Initiative (Kawarabi) (A Project Methodology Paper).Turkish archives of pediatrics · 2025Article
- Multisystem inflammatory syndrome in children and Kawasaki disease.Frontiers in immunology · 2025Review
- The Central Role of Interleukin-1 Signalling in the Pathogenesis of Kawasaki Disease Vasculitis: Path to Translation.The Canadian journal of cardiology · 2024Review
- Review
- Concomitant Kawasaki Disease and Rotavirus Infection-More Than Just a Coincidence: A Case Report.Tropical medicine and infectious disease · 2023Article
- An Update on Reports of Atypical Presentations of Kawasaki Disease and the Recognition of IVIG Non-Responder Children.Diagnostics (Basel, Switzerland) · 2023Review
- Interleukin-33/ST2 Axis as Potential Biomarker and Therapeutic Target in Kawasaki Disease.Inflammation · 2023Article
- Serum alanine aminotransferase level and intravenous immunoglobulin resistance in patients with kawasaki disease.Clinical rheumatology · 2022Article
- Association of Acute Anti-inflammatory Treatment With Medium-term Outcomes for Coronary Artery Aneurysms in Kawasaki Disease.CJC pediatric and congenital heart disease · 2022Article
- Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome.Physiological research · 2022Review
- Targeting TNF-α for COVID-19: Recent Advanced and Controversies.Frontiers in public health · 2022Review
- Serum sodium level associated with coronary artery lesions in patients with Kawasaki disease.Clinical rheumatology · 2022Article
- Kawasaki Disease With Coronary Artery Lesions Detected at Initial Echocardiography.Journal of the American Heart Association · 2021Article
- Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms.Pediatric rheumatology online journal · 2021Review
- Perspective of Immunopathogenesis and Immunotherapies for Kawasaki Disease.Frontiers in pediatrics · 2021Review
- A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment.Hospital pediatrics · 2021Article
- Kawasaki disease: pathophysiology and insights from mouse models.Nature reviews. Rheumatology · 2020Review
- Shock and unresponsiveness to repeated courses of intravenous immunoglobulin in Kawasaki disease: a nationwide database study.Pediatric research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Despite the administration of intravenous immunoglobulin (IVIg) at a dose of 2 g/kg, approximately 3-5% of children with acute Kawasaki disease (KD) may develop coronary artery aneurysms. IVIg-resistance, defined as recrudescence of fever more than 36 h after IVIg completion, is a risk factor for coronary artery abnormalities. Thus, several adjunctive therapies are being evaluated for use in IVIg-resistant KD patients and in patients with coronary artery abnormalities. In this review the role of some of these adjunctive therapies in treatment of children with KD is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.